Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients undergoing esophagectomy.

Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients undergoing esophagectomy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients undergoing esophagectomy. Abstract Text:

Yoichi Sakurai,Toshihiko Masui,Ikuo Yoshida,Shuhei Tonomura,Mitsutaka Shoji,Yasuko Nakamura,Jun Isogaki,Ichiro Uyama,Yoshiyuki Komori,Masahiro Ochiai,Yoichi Sakurai,Toshihiko Masui,Ikuo Yoshida,Shuhei Tonomura,Mitsutaka Shoji,Yasuko Nakamura,Jun Isogaki,Ichiro Uyama,Yoshiyuki Komori,Masahiro Ochiai,

BACKGROUND: Although perioperative immune-enhancing enteral formula (IEEF) is effective to decrease the rate of infectious complications, it is not clear whether perioperative use of IEEF decreases the incidence of postoperative complications and improves clinical outcome in patients who have undergone esophagectomy. A prospective randomized clinical trial was performed to examine the effects of perioperative IEEF on nutritional and immunological status in patients with esophageal carcinoma who have been treated with esophagectomy. METHODS: A total of 30 patients were randomly assigned to two groups, each receiving 3 days of preoperative and postoperative enteral nutrition through jejunostomy started within 24 h after operation, either with immune-enhancing enteral formula (group IEEF, n = 16) or with regular polymeric enteral formula (group C, n = 14). Preoperative and postoperative nutritional and immunological parameters and clinical outcome were examined. RESULTS: A significant increase in the serum concentration of ornithine was noted in group IEEF and it peaked at 5 days after surgery. The equivalent values were significantly lower in group C. There was no difference in serum dochosahexaic acid between the two groups. The n-3/n-6 fatty acid ratio in group IEEF was significantly higher than in group C at 7 days after surgery. Peripheral percent lymphocyte fraction and total lymphocyte count in group IEEF were both significantly higher than those in group C. While T cell fraction of peripheral lymphocytes in group IEEF at 3 days after surgery, B cell fraction in group IEEF at 5 and 7 days after surgery was significantly higher than those in group C, suggesting that perioperative IEEF caused a shift towards B cell proliferation. CONCLUSIONS: Perioperative use of IEEF caused a significant increase in the total lymphocyte count at 3 and 5 days after operation and caused a shift toward B cell proliferation, which may possibly be beneficial to decrease the incidence of postoperative infectious complications.

Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients undergoing esophagectomy. Publishing Authors By Initials

Y Sakurai,T Masui,I Yoshida,S Tonomura,M Shoji,Y Nakamura,J Isogaki,I Uyama,Y Komori,M Ochiai,Y Sakurai,T Masui,I Yoshida,S Tonomura,M Shoji,Y Nakamura,J Isogaki,I Uyama,Y Komori,M Ochiai,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients undergoing esophagectomy. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: World journal of surgery

VOLUME: 31

Page Numbers: 2150-7; discussion 2158-9

Journal Abbreviation:

ISSN: 0364-2313

DAY: 18

MONTH: Nov

YEAR: 2007

Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients undergoing esophagectomy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7704052

Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients undergoing esophagectomy. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients undergoing esophagectomy. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients undergoing esophagectomy.

AFFILIATION: Department of Surgery, Fujita Health University School of Medicine, 1-98 Dengakugakubo Kutsukake-cho, Toyoake Aichi 470-1192, Japan. ysakurai@fujita-hu.ac.jp

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: World J Surg

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients undergoing esophagectomy Related Publications

• Addition to electron deficient olefins of alpha-oxy carbon- centered radicals, generated from cyclic ethers and acetals by the reaction with alkylperoxy- lambda(3)-iodane.
• Butyric Acid induces apoptosis in inflamed fibroblasts.
• Calcium phosphate coating formed in infusion fluid mixture to enhance fixation strength of titanium screws.
• Cancer therapy with local oncolysis and topical cytokine secretion.
• Characterization of ribosomes in the cellular slime mold, Dictyostelium discoideum.
• Combination of direct intratumoral administration of dendritic cells and irradiation induces strong systemic antitumor effect mediated by GRP94/gp96 against squamous cell carcinoma in mice.
• Detail histologic analysis of nerve plexus invasion in invasive ductal carcinoma of the pancreas and its prognostic impact.
• Developmentally regulated glycoprotein alterations in Dictyostelium discoideum.
• Evaluation of the hepatic blood flow increase in the cases with liver metastasis and prediction of patent cases of liver metastasis using dynamic CT.
• Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells.
• Have surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience.
• Hyperbaric oxygen therapy for the treatment of postoperative paralytic ileus and adhesive intestinal obstruction associated with abdominal surgery: experience with 626 patients.
• Improved Surgical Results in Thoracic Esophageal Squamous Cell Carcinoma: A 40-year Analysis of 792 Patients.
• Intersegmental arterial communication between the medial and left lateral segments of the liver.
• Long-term Results after Dissection of Positive Thoracic Lymph Nodes in Patients with Esophageal Squamous Cell Carcinoma.
• Monoclonal antibodies against discoidin I and discoidin II of the cellular slime mold, Dictyostelium discoideum.
• Monoclonal antibodies against the mercaptoethanol-sensitive structure of a cell-cell adhesion protein of Polysphondylium pallidum.
• Perfusion CT can predict the response to chemoradiation therapy and survival in esophageal squamous cell carcinoma: initial clinical results.
• Purification and characterization of alanine dehydrogenase from a cyanobacterium, Phormidium lapideum.
• Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients undergoing esophagectomy.
• Repair of large full-thickness articular cartilage defects by transplantation of autologous uncultured bone-marrow-derived mononuclear cells.
• The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells.
• The lymphatic infiltration identified by d2-40 monoclonal antibody predicts lymph node metastasis in submucosal invasive colorectal cancer.
• Toxic epidermal necrolysis induced by a triple-drug regimen for helicobacter pylori eradication.
• Transcription and noise in negative feedback loops.
• Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients.
• Ventral pancreatectomy associated with segmental duodenectomy including the major papilla.
• [A need for more active cooperation between the nursing and nutrition departments of a hospital]
• [CLINICAL TREATMENT OF RESISTANCE SHIGELLOSIS.]
• [Two cases treated with trastuzumab as primary chemotherapy]